Reason for request
Reassessment of medicines containing methylphenidate in attention deficit hyperactivity disorder in response to the instruction from the Directorate-General for Health.
Clinical Benefit
| Substantial |
The actual benefit of QUASYM LP proprietary products is substantial in the context of the overall therapeutic management of ADHD in children aged 6 years old and over when psychological, educational and social management alone prove insufficient. |
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
gGZpkBg6aXfDagjk
